

AMENDMENTS TO THE CLAIMS

Kindly amend claims 1, 2, 4, 6, and 7, cancel claim 3, and add claims 11-16 as follows.

1. (Currently amended) A method of decreasing proliferation of an abnormally proliferating cell having decreased Sal2 protein levels, a Sal2 protein of altered molecular weight, or a proliferative disease-associated alteration in a Sal2 nucleic acid sequence relative to a normally proliferating cell, said method comprising the step of contacting said abnormally proliferating cell with a *Sal2* nucleic acid sequence having at least 90% identity to the sequence of SEQ ID NO: 2 or SEQ ID NO: 4, wherein said contacting results in the expression of a *Sal2* polypeptide having tumor suppressive activity in said abnormally proliferating cell and decreases proliferation of said cell.
2. (Currently amended) The method of claim 1, wherein said *Sal2* polypeptide comprises the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3.
3. (Cancelled)
4. (Currently amended) The method of claim 3-1, wherein said proliferative disease-associated alteration comprises a *Sal2* nucleic acid sequence that encodes a polypeptide that contains a substitution of a Cys for the Ser at position 73 of SEQ ID NO:1.
5. (Original) The method of claim 1, wherein said abnormally proliferating cell is an ovarian cell.
6. (Currently amended) A method of decreasing DNA tumor virus replication and dissemination said method comprising the step of contacting a cell infected with a DNA

tumor virus and having decreased Sal2 protein levels, a Sal2 protein of altered molecular weight, or a proliferative disease-associated alteration in a Sal2 nucleic acid sequence relative to a non-infected cell with a *Sal2* nucleic acid sequence having at least 90 % identity to the sequence of SEQ ID NO:2 or SEQ ID NO:4, wherein said contacting results in the expression of a Sal2 polypeptide in said cell infected with said DNA tumor virus and prevents said DNA tumor virus from replicating and disseminating.

7. (Currently amended) The method of claim 6, wherein said Sal2 polypeptide comprises the amino acid sequence provided in SEQ ID NO: 1 or SEQ ID NO: 3.

8. (Original) The method of claim 6, wherein said DNA tumor virus is selected from the group consisting of simian virus 40, human polyoma virus, herpes virus, primate adenoviruses, parvovirus, and papilloma virus.

9. (Original) An isolated Sal2 nucleic acid sequence encoding a polypeptide that contains a substitution of a Cys for the Ser at position 73 of SEQ ID NO:1.

10. (Original) The Sal2 nucleic acid sequence of claim 9, wherein said Sal2 nucleic acid sequence is a human *Sal2* nucleic acid sequence.

11. (New) The method of claim 1, wherein said contacting comprises administering to a mammal having a proliferative disease said *Sal2* nucleic acid sequence.

12. (New) The method of claim 11, wherein said *Sal2* nucleic acid is administered by intratumoral injection or by perfusion into blood vessels supplying target organ.

13. (New) The method of claim 1, wherein said *Sal2* nucleic acid is an expression vector selected from the group consisting of an adenovirus, retrovirus, vaccinia viral vector, or recombinant adeno-associated virus.

14. (New) The method of claim 1, wherein said *Sal2* nucleic acid is under the control of a tissue-specific promoter.

15. (New) The method of claim 6, wherein said contacting comprises administering to a mammal infected with said virus an expression vector comprising said *Sal2* nucleic acid.

16. (New) The method of claim 1, wherein said proliferative disease-associated alteration comprises a *Sal2* nucleic acid sequence that encodes a polypeptide that contains a substitution of an Arg for the Gly at amino acid position 744 of SEQ ID NO:1.